| Title |
Treatment of Older Patients with High-Risk Myelodysplastic Syndromes (MDS): The Emerging Role of Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT)
|
|---|---|
| Published in |
Current Hematologic Malignancy Reports, January 2014
|
| DOI | 10.1007/s11899-013-0195-9 |
| Pubmed ID | |
| Authors |
Ehab Atallah, Kathryn Bylow, Jesse Troy, Wael Saber |
| Abstract |
MDS are myeloid clonal hematologic disorders that are most commonly diagnosed in the seventh decade of life. Several treatment options are currently available. However, allo HSCT remains the only curative therapy. Unfortunately, despite the higher incidence of MDS in the older population, less than 10 % of patients undergoing allo HSCT for MDS are > 65 years old. In this paper we discuss the various treatment options in older patients with high-risk MDS with particular emphasis on the role of allo HSCT in older MDS patients. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 40% |
| Unknown | 3 | 60% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 2 | 40% |
| Members of the public | 2 | 40% |
| Science communicators (journalists, bloggers, editors) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 25 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 4 | 16% |
| Student > Ph. D. Student | 4 | 16% |
| Other | 3 | 12% |
| Student > Doctoral Student | 2 | 8% |
| Student > Bachelor | 2 | 8% |
| Other | 5 | 20% |
| Unknown | 5 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 44% |
| Biochemistry, Genetics and Molecular Biology | 3 | 12% |
| Agricultural and Biological Sciences | 1 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Chemistry | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 7 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 May 2016.
All research outputs
#13,167,856
of 22,739,983 outputs
Outputs from Current Hematologic Malignancy Reports
#220
of 427 outputs
Outputs of similar age
#159,800
of 304,743 outputs
Outputs of similar age from Current Hematologic Malignancy Reports
#5
of 10 outputs
Altmetric has tracked 22,739,983 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 427 research outputs from this source. They receive a mean Attention Score of 4.9. This one is in the 47th percentile – i.e., 47% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 304,743 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.